## SYK: Stryker Corporation - XLV: Healthcare

### Executive Summary

No thesis match: MRS_10 -3.1% below STRENGTH zone (3.0-6.0%); PEG 1.47 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-1.7% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($350.53)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 7, Bearish: 0)

**1. Stryker names Spencer Stiles as COO**
- Source: MedTech Dive | 20251204T222217 | Somewhat-Bullish | Relevance: 100%
- Stryker has promoted Spencer Stiles to president and chief operating officer, effective January 1. Stiles, who has been with the company for 27 years, will oversee Strykerâ€™s global business, strategy, and mergers and acquisitions. Concurrently, Dylan Crotty will take over Stiles' previous role as group president of orthopedics.

**2. Stryker promotes Spencer Stiles to president, COO**
- Source: MassDevice | 20251204T140034 | Bullish | Relevance: 100%
- Stryker (NYSE: SYK) has announced the promotion of Spencer Stiles to president and chief operating officer (COO), effective January 1, 2026. Stiles, a 27-year veteran of the company, will oversee global business, strategy, and M&A efforts. Dylan Crotty will succeed Stiles as president of Orthopaedics.

**3. Stryker names Spencer Stiles President and Chief Operating Officer**
- Source: GlobeNewswire | 20251204T130849 | Bullish | Relevance: 100%
- Stryker Corporation has appointed Spencer Stiles as President and Chief Operating Officer, effective January 1, 2026. Stiles, a 27-year veteran of the company, will oversee global businesses, strategy, and M&A. Dylan Crotty will succeed Stiles as Group President, Orthopaedics.

**4. Stryker names Spencer Stiles President and Chief Operating Officer**
- Source: GlobeNewswire | 20251204T083000 | Bullish | Relevance: 100%
- Stryker (NYSE:SYK) has appointed Spencer Stiles as President and Chief Operating Officer, effective January 1, 2026. Stiles, a 27-year veteran of the company, will be responsible for leading Stryker's global businesses, strategy, and mergers and acquisitions. Concurrently, Dylan Crotty will be promoted to Group President, Orthopaedics, succeeding Stiles in that role.

**5. Stryker Appoints Spencer Stiles as New COO**
- Source: TipRanks | 20251204T220934 | Bullish | Relevance: 100%
- Stryker has announced the appointment of Spencer Stiles as President and Chief Operating Officer, effective January 1, 2026. Stiles, a 27-year veteran, will oversee global businesses, strategy, and M&A, aiming to sustain high growth. Dylan Crotty will succeed Stiles as Group President, Orthopaedics.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-11-14 | Truist Securiti | $400 | $392 | +2% |
| 2025-11-14 | Wells Fargo | $456 | $452 | +1% |
| 2025-11-14 | Needham | $448 | $448 | 0% |
| 2025-11-14 | BTIG | $410 | $410 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-11-14 | Truist Securiti | main | Hold |
| 2025-11-14 | Wells Fargo | main | Overweight |
| 2025-11-14 | Needham | reit | Buy |
| 2025-11-14 | BTIG | reit | Buy |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 1 ($0.76M) |
| Sells | 7 ($21.05M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 40.1% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 8.8% (+0.8%)
- Blackrock Inc.: 7.0% (+0.4%)
- JPMORGAN CHASE & CO: 6.2% (+95.3%)
- Greenleaf Trust: 4.3% (-0.3%)
- State Street Corpora: 3.9% (-0.1%)

### Key Risks

1. Heavy insider selling: $21M sold (7 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.47 suggests fair value with growth premium. Forward P/E 24.4x stretched relative to 10% growth. Balance sheet: $1.4B free cash flow. Insider selling cluster ($21.1M in 90 days), potential headwind. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $135.5B |
| Beta | 0.90 |
| 52W Range | $329.16 - $406.19 |
| Short Interest | 1.2% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.47 |
| Forward P/E | 24.4 |
| Current P/E | 26.9 |
| YoY Growth | 10.3% |
| EPS Direction | STABLE |

### Technicals

MRS_10 deteriorating from -1.4% to -3.1% (-1.7% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.1pp (needs >3.0% for momentum thesis). Below SMA200 (0.97x), long-term trend not supportive. RSI neutral at 47. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -3.13% (CS: 18) | Weak |
| RSI_14 | 46.6 | Neutral |
| MACD Histogram | 0.35 | Bullish |
| vs SMA20 | 0.998x | Below |
| vs SMA50 | 0.989x | Below |
| vs SMA200 | 0.966x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $364.35
- **Stop Loss:** $350.53 (3.8% risk)
- **Target:** $378.17 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 36
- **Position Value:** $13,116.60
- **Portfolio %:** 13.12%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with moderate risk appetite and mixed signals. VIX at 15.78 indicates calm conditions but breadth at 53% suggests narrow participation. Fed policy remains neutral with 42 days to next meeting, supporting steady positioning with sector selectivity.*

### Earnings

**Next:** 2026-01-27 (Est: $4.39)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $3.13 | $3.19 | +1.9% |
| 2025Q2 | $3.07 | $3.13 | +1.9% |
| 2025Q1 | $2.73 | $2.84 | +4.0% |
| 2024Q4 | $3.87 | $4.01 | +3.5% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*